MRK Q2 2026 Earnings Call Summary

Merck & Company (MRK) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $16.6 billion, a 5% increase year-over-year (4% excluding foreign exchange impact).
Oncology Revenue: KEYTRUDA family sales reached $8.4 billion, up 4%, driven by strong uptake in earlier-stage cancers.
Gross Margin: 81.1%, down 1.1 percentage points due to higher inventory reserves.
Operating Expenses: Increased to $12.6 billion, including a $5.7 billion charge for the acquisition of Terns Pharmaceuticals.
Net Loss: Reported loss of $0.13 per share, impacted by a one-time charge of $2.31 per share from the Terns acquisition.
2026 Non-GAAP Guidance: Revenue expected between $66.3 billion and $67.3 billion, with EPS guidance of $2.66 to $2.76.

2. Strategic Updates and Business Highlights

New Product Launches: Successful launch of LIPFENDRA, the first oral PCSK9 inhibitor approved by the FDA, aimed at reducing LDL cholesterol.
Oncology Portfolio: Continued success with KEYTRUDA, including new approvals and positive data from clinical trials, particularly for sac-TMT and WELIREG.
Acquisition: Completed acquisition of Terns Pharmaceuticals, enhancing the hematology pipeline with MK-4208 for chronic myeloid leukemia.
Pipeline Progress: Advancements in cardiometabolic, immunology, and infectious disease areas, including promising data from tulisokibart for ulcerative colitis and ongoing HIV developments.

3. Forward Guidance and Outlook

Revenue Growth: Confident in achieving 2% to 4% growth for the full year, supported by new product launches and pipeline advancements.
Investment Focus: Continued investment in innovative medicines and vaccines, with a commitment to capital allocation for growth and shareholder returns.
Long-Term Confidence: Management expressed optimism about the company’s future, particularly regarding the $70 billion commercial opportunity from over 20 new products expected to drive growth into the next decade.

4. Bad News, Challenges, or Points of Concern

Net Loss: The reported loss reflects significant one-time charges, raising concerns about short-term profitability.
KEYTRUDA Growth Moderation: Anticipated slowdown in U.S. KEYTRUDA sales growth as market penetration reaches peak levels.
Competition and Market Dynamics: The need to differentiate sac-TMT in a competitive landscape with existing therapies, and the potential impact of generic competition on other products.
Regulatory and Access Challenges: While LIPFENDRA has a strong label, establishing broad access may take time, and initial uptake could be slower than expected.

5. Notable Q&A Insights

Pipeline Derisking: Management noted faster-than-expected clinical derisking of key products, enhancing confidence in achieving the projected $70 billion opportunity.
LIPFENDRA Launch Strategy: Focus on expanding the market rather than taking share from existing injectable PCSK9 therapies, with an emphasis on educating primary care providers.
TL1A Combination Strategies: Ongoing evaluations of TL1A for various indications, with a focus on safety and efficacy in combination therapies.
PD-1/VEGF Development: Interest in exploring combination trials with PD-1/VEGF agents, leveraging existing data and unique assets within Merck’s portfolio.

Overall, Merck's Q2 2026 results reflect a solid performance driven by strategic product launches and a robust pipeline, despite facing challenges related to profitability and market dynamics. The company remains optimistic about its future growth prospects.

MRK — Merck & Co., Inc.